SCHEMBL6785384

SCHEMBL6785384

Cn1ncc2[nH]c3ccc(Cc4ccc(Cl)cc4)cc3c(=O)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNC P24863 1/20 0.40
CDK8 P49336 1/20 0.40
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
PRMT5 O14744 2/20 0.37
WDR77 Q9BQA1 2/20 0.37
CNR1 P21554 2/20 0.37
LMNA P02545 4/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
MEN1 O00255 1/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
MAOB P27338 1/20 0.35
NTRK1 P04629 1/20 0.35
MAPT P10636 1/20 0.35
CHUK O15111 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6785787 0.90 PRMT5 (0.39) PRMT5WDR77CNR1GABRA1GABRB2
SCHEMBL6785795 0.89 GABRA1 (0.44) GABRA1GABRB2ALDH1A1POLB
SCHEMBL6786766 0.88 PRMT5 (0.36) PRMT5WDR77LMNACYP2C9HPGD
SCHEMBL6782572 0.88 KIF11 (0.38) LMNACYP2C9HPGDGABRA1GABRB2
SCHEMBL6785495 0.88 HPGD (0.36) PRMT5WDR77LMNACYP2C9HPGD
SCHEMBL6785560 0.86 ABCG2 (0.42) PRMT5WDR77MEN1ALDH1A1POLB
SCHEMBL6784477 0.85 CHUK (0.38) PRMT5WDR77LMNACYP2C9HPGD
SCHEMBL6784689 0.84 PRMT5 (0.37) PRMT5WDR77LMNAMEN1POLB
SCHEMBL6789023 0.84 SMN1; SMN2 (0.47) PRMT5WDR77GABRA1GABRB2ALDH1A1
SCHEMBL6788272 0.83 GABRA1 (0.48) CYP2C9GABRA1GABRB2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6686373-B2 ANALGESICS; ANTIINFLAMMATORY AGENT WARNER-LAMBERT COMPANY LLC 2004-02-03 US claimed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US claimed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP claimed
US-6686373-B2 ANALGESICS; ANTIINFLAMMATORY AGENT WARNER-LAMBERT COMPANY LLC 2004-02-03 US disclosed
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors KAWAMURA KIYOSHI (JP) 2003-07-10 US disclosed
EP-1310498-A2 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PFIZER INC. (US) 2003-05-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130277-A1 Pyrazoloquinolinone derivatives as protein kinase C inhibitors PRKCB, PRKCA, PRKCG CCNC 605/4885CDK8 787/4885PDE3B 1908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.